表紙
市場調查報告書

肝癌診斷檢驗的全球市場:醫療設備的開發平台評估

Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019

出版商 GlobalData 商品編碼 372542
出版日期 內容資訊 英文 132 Pages
訂單完成後即時交付
價格
Back to Top
肝癌診斷檢驗的全球市場:醫療設備的開發平台評估 Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019
出版日期: 2019年11月14日內容資訊: 英文 132 Pages
簡介

本報告提供全球肝癌診斷檢驗相關產品市場上,主要的開發中產品與其臨床實驗的進展調查,提供產品功能·特性比較分析 (臨床實驗的各進展階段) ,再彙整主要企業簡介及代表性產品,近來的市場動靜 (業績報告·資本交易趨勢等) 資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 肝癌診斷檢驗概要

第3章 臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各地區
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期

第4章 臨床實驗中的開發中產品:各企業

  • 肝癌診斷檢驗的企業:各臨床實驗階段的開發中產品
  • 肝癌診斷檢驗:各臨床實驗階段的開發中產品

第5章 肝癌診斷檢驗市場:企業·產品概要

  • Abbott Diagnostics
  • Abcodia Ltd.
  • AXO Science S.A.S.
  • BioMark Technologies Inc.
  • China Sky One Medical, Inc.
  • Digna Biotech, S.L.
  • Drexel University
  • German Cancer Research Center
  • Glycotest, Inc.
  • Imperial College London
  • IntegraGen SA
  • Matrix-Bio, Inc.
  • NanoString Technologies, Inc.
  • National Cancer Institute
  • Oncimmune (USA) LLC
  • Orion Genomics LLC
  • PleX Diagnostics
  • ProMIS Neurosciences Inc.
  • Proplex Technologies, Llc
  • Proteome Sciences Plc
  • Roche Diagnostics International Ltd.
  • TrovaGene, Inc.
  • University of Rochester
  • Ventana Medical Systems, Inc.
  • Viomics Inc.
  • XEPTAGEN SpA
  • Xiamen Zeesan Biotech Co.,Ltd

第6章 肝癌診斷檢驗市場市場:目前的趨勢

第7章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0818EPD

GlobalData's Medical Devices sector report, "Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019" provides an overview of Liver Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Liver Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Liver Cancer Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Liver Cancer Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Liver Cancer Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

  • 1.1 List of Tables 5
  • 1.2 List of Figures 7

2 Introduction 8

  • 2.1 Liver Cancer Diagnostic Tests Overview 8

3 Products under Development 9

  • 3.1 Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development 9
  • 3.2 Liver Cancer Diagnostic Tests - Pipeline Products by Territory 10
  • 3.3 Liver Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 11
  • 3.4 Liver Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 12
  • 3.5 Liver Cancer Diagnostic Tests - Ongoing Clinical Trials 13

4 Liver Cancer Diagnostic Tests - Pipeline Products under Development by Companies 14

  • 4.1 Liver Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 14
  • 4.2 Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development 16

5 Liver Cancer Diagnostic Tests Companies and Product Overview 18

  • 5.1 Abbott Diagnostics Company Overview 18
    • 5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 18
  • 5.2 Abcodia Ltd Company Overview 23
    • 5.2.1 Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.3 AXO Science SAS Company Overview 24
    • 5.3.1 AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.4 BioMark Technologies Inc Company Overview 27
    • 5.4.1 BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 27
  • 5.5 Bioprognos SL Company Overview 28
    • 5.5.1 Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.6 China Sky One Medical Inc Company Overview 29
    • 5.6.1 China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.7 Digna Biotech SL Company Overview 30
    • 5.7.1 Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 30
  • 5.8 Exact Sciences Corp Company Overview 32
    • 5.8.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 32
  • 5.9 Fujirebio Diagnostics Inc Company Overview 34
    • 5.9.1 Fujirebio Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 34
  • 5.10 German Cancer Research Center Company Overview 35
    • 5.10.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 35
  • 5.11 Glycotest Inc Company Overview 36
    • 5.11.1 Glycotest Inc Pipeline Products & Ongoing Clinical Trials Overview 36
  • 5.12 ImCare Biotech LLC Company Overview 39
    • 5.12.1 ImCare Biotech LLC Pipeline Products & Ongoing Clinical Trials Overview 39
  • 5.13 Imperial College London Company Overview 40
    • 5.13.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 40
  • 5.14 IntegraGen SA Company Overview 41
    • 5.14.1 IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 41
  • 5.15 Matrix-Bio Inc Company Overview 42
    • 5.15.1 Matrix-Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 42
  • 5.16 MDNA Life Sciences Inc Company Overview 44
    • 5.16.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 44
  • 5.17 Medical University of South Carolina Company Overview 45
    • 5.17.1 Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 45
  • 5.18 Medical University of Vienna Company Overview 46
    • 5.18.1 Medical University of Vienna Pipeline Products & Ongoing Clinical Trials Overview 46
  • 5.19 Memorial Sloan Kettering Cancer Center Company Overview 47
    • 5.19.1 Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 47
  • 5.20 NanoString Technologies Inc Company Overview 48
    • 5.20.1 NanoString Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 48
  • 5.21 Numares AG Company Overview 49
    • 5.21.1 Numares AG Pipeline Products & Ongoing Clinical Trials Overview 49
  • 5.22 Oncimmune (USA) LLC Company Overview 50
    • 5.22.1 Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 50
  • 5.23 Orion Genomics LLC Company Overview 51
    • 5.23.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 51
  • 5.24 PleX Diagnostics Inc (Inactive) Company Overview 52
    • 5.24.1 PleX Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 52
  • 5.25 ProMIS Neurosciences Inc Company Overview 53
    • 5.25.1 ProMIS Neurosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 53
  • 5.26 Proplex Technologies Llc Company Overview 54
    • 5.26.1 Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 54
  • 5.27 Proteome Sciences Plc Company Overview 55
    • 5.27.1 Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 55
  • 5.28 Roche Diagnostics International Ltd Company Overview 56
    • 5.28.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 56
  • 5.29 University of Louisville Company Overview 57
    • 5.29.1 University of Louisville Pipeline Products & Ongoing Clinical Trials Overview 57
  • 5.30 University of Rochester Company Overview 58
    • 5.30.1 University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 58
  • 5.31 Ventana Medical Systems Inc Company Overview 59
    • 5.31.1 Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 59
  • 5.32 Viomics Inc. Company Overview 60
    • 5.32.1 Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 60
  • 5.33 XEPTAGEN SpA Company Overview 61
    • 5.33.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 61
  • 5.34 Ymir Genomics LLC. Company Overview 65
    • 5.34.1 Ymir Genomics LLC. Pipeline Products & Ongoing Clinical Trials Overview 65

6 Liver Cancer Diagnostic Tests - Recent Developments 66

  • 6.1 Nov 05, 2019: Blueprint Medicines outlines precision therapy research vision, provides update on discovery and clinical-stage portfolio at R&D Day and reports third quarter 2019 financial results 66
  • 6.2 Oct 31, 2019: Proteome Sciences: Trading update and announcement of Board Changes 68
  • 6.3 Oct 30, 2019: PerkinElmer announces financial results for the third quarter of 2019 69
  • 6.4 Oct 29, 2019: Pfizer reports third-quarter 2019 results 70
  • 6.5 Sep 27, 2019: Ian Read to retire as executive chairman of Pfizer's board of directors; chief executive Officer Dr. Albert Bourla named chairman 77
  • 6.6 Sep 05, 2019: Simple CEUS Scan helps diagnose Liver Cancer when MRI is uncertain 78
  • 6.7 Aug 27, 2019: ProMIS Neurosciences appoints Internationally Recognized Researcher in Alzheimer's Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board 79

7 Appendix 129

  • 7.1 Methodology 129
  • 7.2 About GlobalData 132
  • 7.3 Contact Us 132
  • 7.4 Disclaimer 132

List of Tables

  • Table 1: Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development 11
  • Table 2: Liver Cancer Diagnostic Tests - Pipeline Products by Territory 12
  • Table 3: Liver Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 13
  • Table 4: Liver Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 14
  • Table 5: Liver Cancer Diagnostic Tests - Ongoing Clinical Trials 15
  • Table 6: Liver Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 16
  • Table 7: Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development 18
  • Table 8: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 20
  • Table 9: ARCHITECT c16000 System - PIVKA Assay - Product Status 20
  • Table 10: ARCHITECT c16000 System - PIVKA Assay - Product Description 21
  • Table 11: ARCHITECT c4000 System - PIVKA Assay - Product Status 21
  • Table 12: ARCHITECT c4000 System - PIVKA Assay - Product Description 21
  • Table 13: ARCHITECT c8000 System - PIVKA Assay - Product Status 21
  • Table 14: ARCHITECT c8000 System - PIVKA Assay - Product Description 22
  • Table 15: ARCHITECT ci16200 Integrated System - PIVKA Assay - Product Status 22
  • Table 16: ARCHITECT ci16200 Integrated System - PIVKA Assay - Product Description 22
  • Table 17: ARCHITECT ci4100 Integrated System - PIVKA Assay - Product Status 22
  • Table 18: ARCHITECT ci4100 Integrated System - PIVKA Assay - Product Description 23
  • Table 19: ARCHITECT ci8200 Integrated System - PIVKA Assay - Product Status 23
  • Table 20: ARCHITECT ci8200 Integrated System - PIVKA Assay - Product Description 23
  • Table 21: ARCHITECT i4000SR System - PIVKA II Assay - Product Status 24
  • Table 22: ARCHITECT i4000SR System - PIVKA II Assay - Product Description 24
  • Table 23: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 24: Biomarker Test - Liver Cancer Diagnostic Tests - Product Status 25
  • Table 25: Biomarker Test - Liver Cancer Diagnostic Tests - Product Description 25
  • Table 26: AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview 26
  • Table 27: Multiplexed Detection - Des-Carboxy Prothrombin - Product Status 26
  • Table 28: Multiplexed Detection - Des-Carboxy Prothrombin - Product Description 26
  • Table 29: Multiplexed Detection - Matrix metalloproteinase 1 - Product Status 27
  • Table 30: Multiplexed Detection - Matrix metalloproteinase 1 - Product Description 27
  • Table 31: Multiplexed Detection - Procollagen type III N-terminal peptide - Product Status 27
  • Table 32: Multiplexed Detection - Procollagen type III N-terminal peptide - Product Description 28
  • Table 33: BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 29
  • Table 34: Biomarker Assay - Hepatocellular Cancer - Product Status 29
  • Table 35: Biomarker Assay - Hepatocellular Cancer - Product Description 29
  • Table 36: Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 37: MBDAA Liver Cancer Test - Product Status 30
  • Table 38: MBDAA Liver Cancer Test - Product Description 30
  • Table 39: China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 40: Diagnostic Kit - Liver Cancer Diagnostic Tests - Product Status 31
  • Table 41: Diagnostic Kit - Liver Cancer Diagnostic Tests - Product Description 31
  • Table 42: Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 43: HCC Molecular Marker Assay - Product Status 32
  • Table 44: HCC Molecular Marker Assay - Product Description 32
  • Table 45: Oxidated APO-A1 Assay - Product Status 33
  • Table 46: Oxidated APO-A1 Assay - Product Description 33
  • Table 47: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 34
  • Table 48: Blood-based Liver Cancer Test - Product Status 34
  • Table 49: Blood-based Liver Cancer Test - Product Description 34
  • Table 50: DNA Biomarkers - Hepatocellular Carcinoma - Product Status 35
  • Table 51: DNA Biomarkers - Hepatocellular Carcinoma - Product Description 35
  • Table 52: Fujirebio Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 53: Lumipulse G - PIVKA-II Assay - Product Status 36
  • Table 54: Lumipulse G - PIVKA-II Assay - Product Description 36
  • Table 55: German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 56: RAGE Based Diagnostic Assay - Liver Cancer Diagnostic Tests - Product Status 37
  • Table 57: RAGE Based Diagnostic Assay - Liver Cancer Diagnostic Tests - Product Description 37
  • Table 58: Glycotest Inc Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 59: HCC Panel - Product Status 38
  • Table 60: HCC Panel - Product Description 38

List of Figures

  • Figure 1: Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development 9
  • Figure 2: Liver Cancer Diagnostic Tests - Pipeline Products by Territory 10
  • Figure 3: Liver Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 11
  • Figure 4: Liver Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 12
  • Figure 5: Liver Cancer Diagnostic Tests - Ongoing Clinical Trials 13
Back to Top